674 related articles for article (PubMed ID: 25247697)
41. Genome dependent Cas9/gRNA search time underlies sequence dependent gRNA activity.
Moreb EA; Lynch MD
Nat Commun; 2021 Aug; 12(1):5034. PubMed ID: 34413309
[TBL] [Abstract][Full Text] [Related]
42. Distinct patterns of Cas9 mismatch tolerance in vitro and in vivo.
Fu BX; St Onge RP; Fire AZ; Smith JD
Nucleic Acids Res; 2016 Jun; 44(11):5365-77. PubMed ID: 27198218
[TBL] [Abstract][Full Text] [Related]
43. Selection of extended CRISPR RNAs with enhanced targeting and specificity.
Herring-Nicholas A; Dimig H; Roesing MR; Josephs EA
Commun Biol; 2024 Jan; 7(1):86. PubMed ID: 38212640
[TBL] [Abstract][Full Text] [Related]
44. A detailed cell-free transcription-translation-based assay to decipher CRISPR protospacer-adjacent motifs.
Maxwell CS; Jacobsen T; Marshall R; Noireaux V; Beisel CL
Methods; 2018 Jul; 143():48-57. PubMed ID: 29486239
[TBL] [Abstract][Full Text] [Related]
45. Boosting CRISPR/Cas9 multiplex editing capability with the endogenous tRNA-processing system.
Xie K; Minkenberg B; Yang Y
Proc Natl Acad Sci U S A; 2015 Mar; 112(11):3570-5. PubMed ID: 25733849
[TBL] [Abstract][Full Text] [Related]
46. An improved method for precise genome editing in zebrafish using CRISPR-Cas9 technique.
Gasanov EV; Jędrychowska J; Pastor M; Wiweger M; Methner A; Korzh VP
Mol Biol Rep; 2021 Feb; 48(2):1951-1957. PubMed ID: 33481178
[TBL] [Abstract][Full Text] [Related]
47. Computational Design of gRNAs Targeting Genetic Variants Across HIV-1 Subtypes for CRISPR-Mediated Antiviral Therapy.
Chung CH; Allen AG; Atkins A; Link RW; Nonnemacher MR; Dampier W; Wigdahl B
Front Cell Infect Microbiol; 2021; 11():593077. PubMed ID: 33768011
[TBL] [Abstract][Full Text] [Related]
48. CRISPR multitargeter: a web tool to find common and unique CRISPR single guide RNA targets in a set of similar sequences.
Prykhozhij SV; Rajan V; Gaston D; Berman JN
PLoS One; 2015; 10(3):e0119372. PubMed ID: 25742428
[TBL] [Abstract][Full Text] [Related]
49. Internal guide RNA interactions interfere with Cas9-mediated cleavage.
Thyme SB; Akhmetova L; Montague TG; Valen E; Schier AF
Nat Commun; 2016 Jun; 7():11750. PubMed ID: 27282953
[TBL] [Abstract][Full Text] [Related]
50. CRISPR-Cas "Non-Target" Sites Inhibit On-Target Cutting Rates.
Moreb EA; Hutmacher M; Lynch MD
CRISPR J; 2020 Dec; 3(6):550-561. PubMed ID: 33346713
[TBL] [Abstract][Full Text] [Related]
51. Analysis of CRISPR/Cas9 Guide RNA Efficiency and Specificity Against Genetically Diverse HIV-1 Isolates.
Sessions KJ; Chen YY; Hodge CA; Hudson TR; Eszterhas SK; Hayden MS; Howell AL
AIDS Res Hum Retroviruses; 2020 Oct; 36(10):862-874. PubMed ID: 32640832
[TBL] [Abstract][Full Text] [Related]
52. Enhancing CRISPR-Cas9 gRNA efficiency prediction by data integration and deep learning.
Xiang X; Corsi GI; Anthon C; Qu K; Pan X; Liang X; Han P; Dong Z; Liu L; Zhong J; Ma T; Wang J; Zhang X; Jiang H; Xu F; Liu X; Xu X; Wang J; Yang H; Bolund L; Church GM; Lin L; Gorodkin J; Luo Y
Nat Commun; 2021 May; 12(1):3238. PubMed ID: 34050182
[TBL] [Abstract][Full Text] [Related]
53. Key sequence features of CRISPR RNA for dual-guide CRISPR-Cas9 ribonucleoprotein complexes assembled with wild-type or HiFi Cas9.
Okada K; Aoki K; Tabei T; Sugio K; Imai K; Bonkohara Y; Kamachi Y
Nucleic Acids Res; 2022 Mar; 50(5):2854-2871. PubMed ID: 35166844
[TBL] [Abstract][Full Text] [Related]
54. Broad-Spectrum and Personalized Guide RNAs for CRISPR/Cas9 HIV-1 Therapeutics.
Dampier W; Sullivan NT; Mell JC; Pirrone V; Ehrlich GD; Chung CH; Allen AG; DeSimone M; Zhong W; Kercher K; Passic S; Williams JW; Szep Z; Khalili K; Jacobson JM; Nonnemacher MR; Wigdahl B
AIDS Res Hum Retroviruses; 2018 Nov; 34(11):950-960. PubMed ID: 29968495
[TBL] [Abstract][Full Text] [Related]
55. Position of Deltaproteobacteria Cas12e nuclease cleavage sites depends on spacer length of guide RNA.
Selkova P; Vasileva A; Pobegalov G; Musharova O; Arseniev A; Kazalov M; Zyubko T; Shcheglova N; Artamonova T; Khodorkovskii M; Severinov K; Fedorova I
RNA Biol; 2020 Oct; 17(10):1472-1479. PubMed ID: 32564655
[TBL] [Abstract][Full Text] [Related]
56. Conformational control of Cas9 by CRISPR hybrid RNA-DNA guides mitigates off-target activity in T cells.
Donohoue PD; Pacesa M; Lau E; Vidal B; Irby MJ; Nyer DB; Rotstein T; Banh L; Toh MS; Gibson J; Kohrs B; Baek K; Owen ALG; Slorach EM; van Overbeek M; Fuller CK; May AP; Jinek M; Cameron P
Mol Cell; 2021 Sep; 81(17):3637-3649.e5. PubMed ID: 34478654
[TBL] [Abstract][Full Text] [Related]
57. Probing the structural dynamics of the CRISPR-Cas9 RNA-guided DNA-cleavage system by coarse-grained modeling.
Zheng W
Proteins; 2017 Feb; 85(2):342-353. PubMed ID: 27936513
[TBL] [Abstract][Full Text] [Related]
58. Necessity for Validation of Effectiveness of Selected Guide RNA In Silico for Application of CRISPR/Cas9.
Kim DH; Lee J; Suh Y; Lee K
Mol Biotechnol; 2021 Feb; 63(2):140-149. PubMed ID: 33386580
[TBL] [Abstract][Full Text] [Related]
59. CRISPR/Cas9 mediated high efficiency knockout of the eye color gene Vermillion in Helicoverpa zea (Boddie).
Perera OP; Little NS; Pierce CA
PLoS One; 2018; 13(5):e0197567. PubMed ID: 29771955
[TBL] [Abstract][Full Text] [Related]
60. Methods for Optimizing CRISPR-Cas9 Genome Editing Specificity.
Tycko J; Myer VE; Hsu PD
Mol Cell; 2016 Aug; 63(3):355-70. PubMed ID: 27494557
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
